Syn-Ake

Syn-Ake is a synthetic cosmetic peptide ingredient (INCI name: Dipeptide Diaminobutyroyl Benzylamide Diacetate) developed by Pentapharm and now marketed by DSM. The compound is designed as a small-peptide mimetic of waglerin-1, a natural peptide isolated from the venom of the temple viper Tropidolaemus wagleri. Waglerin-1 functions as a nicotinic acetylcholine receptor antagonist, blocking the postsynaptic receptor that normally receives acetylcholine signal at neuromuscular junctions. Syn-Ake reproduces a portion of this mechanism in a synthetic peptide form intended for topical cosmetic use.

The marketing positioning emphasizes the "snake venom" origin as a distinctive selling point. The actual ingredient is a synthetic compound containing no animal-derived material and only a partial mechanistic similarity to waglerin-1. The full snake venom toxin is much more potent and would not be suitable for cosmetic use. Syn-Ake represents a peptide-based attempt to capture a portion of the mechanism in a topically-acceptable form.

Waglerin-1 mechanism. Waglerin-1 is a 22-amino-acid peptide that binds nicotinic acetylcholine receptors at neuromuscular junctions with high selectivity for the muscle-type receptor (alpha-1 subunit). Receptor blockade prevents acetylcholine from initiating muscle contraction, producing flaccid paralysis at toxin concentrations. The selectivity for muscle receptors distinguishes waglerin-1 from many other snake venom toxins.

Syn-Ake design. The synthetic dipeptide reproduces a portion of the waglerin-1 receptor-binding interaction. The compound is much smaller and less potent than the natural toxin, suitable for cosmetic application at concentrations that produce subtle effects rather than dramatic muscle blockade.

The Evidence

Supplier studies describe Syn-Ake formulations producing wrinkle-depth reductions in user studies of finished products. Reported effect magnitudes typically range from 20 to 50 percent reduction in wrinkle depth measurements over 4 to 12 weeks of twice-daily application.

Mechanism work in cell culture and frog neuromuscular preparation studies has examined Syn-Ake effects on acetylcholine receptor function. The published data supports the proposed mechanism at experimental concentrations.

Comparison with Argireline. The two compounds target the same overall outcome (reduced neuromuscular signaling) through different mechanisms (Argireline at SNAP-25 and SNARE complex; Syn-Ake at the acetylcholine receptor). Whether one is meaningfully superior to the other in topical application has not been established by independent head-to-head trials.

Comparison with injected botulinum toxin. Injected botulinum toxin produces near-complete neuromuscular blockade lasting several months with substantial Phase 3 evidence. Topical Syn-Ake produces gradual modest effects on expression-line softening. The two are not in the same tier of clinical effect.

Independent dermatology research on Syn-Ake specifically is limited compared with supplier-generated data.

Regulatory and Legal Status

FDA. No drug approval. Permitted as cosmetic ingredient.

EMA. Cosmetic ingredient status.

INCI. Listed as Dipeptide Diaminobutyroyl Benzylamide Diacetate.

Compounding. Not on FDA bulk drug substances list.

WADA. Not on 2026 Prohibited List.

The proposed mechanism is mimicry of waglerin-1 antagonism at nicotinic acetylcholine receptors.

Neuromuscular junction biology. Muscle contraction at neuromuscular junctions requires acetylcholine release from the presynaptic motor neuron, diffusion across the synaptic cleft, and binding to nicotinic acetylcholine receptors on the postsynaptic muscle fiber. Receptor binding opens cation channels, depolarizes the muscle membrane, and triggers contraction. Blocking the receptor prevents this signaling cascade, producing muscle relaxation.

Waglerin-1 mechanism. The natural snake venom peptide binds the muscle-type nicotinic acetylcholine receptor with high affinity and selectivity. Receptor blockade produces flaccid paralysis at toxin concentrations.

Syn-Ake mechanism. The synthetic compound reproduces a portion of the waglerin-1 receptor-binding interaction. Cell culture studies suggest competitive antagonism of acetylcholine binding at lower affinity than the natural toxin. At cosmetic topical concentrations, the effect is much milder than waglerin-1 itself would produce.

Skin penetration. Topical peptide delivery to facial neuromuscular junctions faces substantial barriers. The stratum corneum limits peptide penetration; the synaptic cleft is anatomically buried in dermal tissue. Whether topical Syn-Ake at cosmetic concentrations achieves sufficient receptor-site concentrations to produce meaningful effects is mechanistically uncertain. The reported clinical effects may reflect partial activity at superficially located receptors or other unrecognized mechanisms.

Pharmacokinetics. Systemic absorption from topical facial application at cosmetic concentrations is minimal. The compound is not designed for or evaluated in systemic administration.

Effects reported in cosmetic-supplier and consumer studies:

• Reduction in expression-line depth, particularly forehead and crow's feet
• Improvement in skin smoothness scores
• Effects gradual over 4 to 12 weeks of twice-daily application
• Generally well-tolerated topical application

Consumer reports from finished-product use describe variable individual responses. The most consistent benefit is on dynamic expression lines visible during muscle contraction. Static wrinkles and structural aging are not significantly addressed.

The expectation-management framing is critical. Topical cosmetic peptides produce subtle, gradual effects. The "snake venom" marketing positioning may create expectations that exceed actual deliverable effects. Users seeking Botox-like outcomes will be disappointed with topical Syn-Ake or any other cosmetic peptide.

Topical cosmetic concentrations for Syn-Ake in marketed products typically range from 1 to 4 percent of the raw material in finished formulation. Higher concentrations exist in specialty serums.

Application frequency is typically once or twice daily to areas of expression lines. Marketing claims for visible effects typically reference 4 to 12 weeks of consistent application.

No injectable, oral, or systemic dosing protocol for Syn-Ake exists or is supported by safety data. The compound is restricted to topical cosmetic use. Importantly, while Syn-Ake is positioned as a mimetic of a snake venom toxin, the actual cosmetic ingredient is far less potent than the parent toxin and is not a meaningful safety concern at topical doses.

Topical Syn-Ake at cosmetic concentrations has an acceptable safety record. Reported reactions:

• Mild local irritation at higher concentrations
• Rare contact dermatitis
• Possible interactions with other actives in formulation

Safety considerations specific to higher-concentration use:

• Effects in pregnancy and breastfeeding have not been formally evaluated; cosmetic use is generally considered acceptable
• Long-term safety of chronic daily application has not been formally characterized in controlled studies
• Theoretical systemic effects from acetylcholine receptor antagonism do not apply at standard cosmetic doses given minimal systemic absorption

Drug-drug interactions with topical retinoids, hydroxy acids, and other cosmetic actives have not been formally studied. Most users tolerate combinations well.

Syn-Ake is most often combined with other cosmetic anti-aging peptides in multi-active formulations:

• Argireline for parallel neuromuscular-mimetic pathways at different mechanistic steps
• SNAP-8 as another SNARE-complex-targeting peptide
• Matrixyl and Matrixyl 3000 for collagen-synthesis claims
• Syn-Coll for TGF-beta-mediated collagen stimulation

The neuromuscular-mimetic peptides (Argireline, SNAP-8, Syn-Ake) are often combined under the assumption that targeting different steps in the neuromuscular signaling cascade produces additive effects. Whether the combination meaningfully exceeds the effect of any single component has not been established in controlled comparative studies.

External comparators in the expression-line treatment landscape include injected botulinum toxin (Botox, Dysport, Xeomin, Daxxify) with substantial Phase 3 evidence and large effect magnitude, dermal fillers for static wrinkle correction, and laser/energy device treatments for skin remodeling. Topical cosmetic peptides sit at the mildest, most accessible end of the intervention spectrum.

For users with significant expression-line concerns, the evidence-based pathway leads through dermatologist consultation and consideration of injectable neuromodulators. Topical peptides like Syn-Ake are reasonable choices for users seeking subtle gradual improvement with high tolerability and no needle exposure.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.